Edition:
United States

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

114.70EUR
14 Jun 2019
Change (% chg)

€-1.20 (-1.04%)
Prev Close
€115.90
Open
€115.70
Day's High
€115.70
Day's Low
€113.10
Volume
121,969
Avg. Vol
122,460
52-wk High
€155.95
52-wk Low
€98.85

Latest Key Developments (Source: Significant Developments)

Ipsen, Debiopharm Extend Their Strategic Decapeptyl Partnership For 15 Years
Wednesday, 12 Jun 2019 12:59am EDT 

June 12 (Reuters) - Ipsen SA ::DEBIOPHARM AND IPSEN EXTEND THEIR STRATEGIC DECAPEPTYL (TRIPTORELIN) PARTNERSHIP FOR ANOTHER 15 YEARS.UNDER THE RENEWED AGREEMENT, BOTH PARTIES WILL CO-DEVELOP NOVEL FORMULATIONS AND EXPLORE ADDITIONAL INDICATIONS FOR OTHER PATIENT POPULATIONS WITH HIGH UNMET NEEDS..  Full Article

Ipsen Reports Double-Digit Sales Growth In Q1 2019
Wednesday, 24 Apr 2019 12:56am EDT 

April 24 (Reuters) - IPSEN SA ::IPSEN REPORTS STRONG DOUBLE-DIGIT SALES GROWTH IN FIRST QUARTER 2019 AND CONFIRMS FULL YEAR 2019 FINANCIAL TARGETS.Q1 GROUP SALES EUR 597.2 MILLION VERSUS EUR 510.3 MILLION YEAR AGO.FULL YEAR 2019 GUIDANCE CONFIRMED.  Full Article

Clementia Pharma Announces Receipt Of Final Court Approval For Plan Of Arrangement With Ipsen S.A.
Thursday, 11 Apr 2019 12:00pm EDT 

April 11 (Reuters) - Clementia Pharmaceuticals Inc ::CLEMENTIA PHARMACEUTICALS INC. ANNOUNCES RECEIPT OF FINAL COURT APPROVAL FOR PLAN OF ARRANGEMENT WITH IPSEN S.A..CLEMENTIA PHARMACEUTICALS INC - CURRENTLY ANTICIPATED THAT ARRANGEMENT WILL BE COMPLETED ON OR ABOUT APRIL 17, 2019.  Full Article

Ipsen To Acquire Clementia Pharmaceuticals
Monday, 25 Feb 2019 01:19am EST 

Feb 25 (Reuters) - IPSEN SA ::IPSEN TO ACQUIRE CLEMENTIA PHARMACEUTICALS TO SIGNIFICANTLY BOOST RARE DISEASE PORTFOLIO.IPSEN TO ACQUIRE ALL OUTSTANDING SHARES OF CLEMENTIA FOR A PURCHASE PRICE OF US$25.00 PER SHARE IN CASH UPFRONT PLUS A CONTINGENT VALUE RIGHT (CVR) OF US$6.00 PER SHARE.  Full Article

Ipsen FY Group Net Sales Rise To 2.22 Billion Euros
Thursday, 14 Feb 2019 01:00am EST 

Feb 14 (Reuters) - IPSEN SA ::IPSEN DELIVERS STRONG 2018 RESULTS AND EXPECTS CONTINUED SALES AND PROFIT GROWTH IN 2019.FY GROUP NET SALES REACHED EUR 2,224.8 MILLION, UP 20.1% YEAR-ON-YEAR..CORE OPERATING INCOME REACHED EUR 659.9 MILLION IN 2018, COMPARED TO EUR 503.6 MILLION IN 2017, A GROWTH OF 31.0%.CORE CONSOLIDATED NET PROFIT WAS EUR 491.6 MILLION IN 2018, AN INCREASE OF 35.5% VERSUS EUR 362.7 MILLION IN 2017.SEES 2019 GROUP SALES GROWTH YEAR-ON-YEAR AT CONSTANT CURRENCY GREATER THAN +13.0%.SEES 2019 CORE OPERATING MARGIN AROUND 31.0% OF NET SALES.  Full Article

Ipsen And 3BP Announce First Patient Dosed In IPN01087 Phase I/II Study
Tuesday, 20 Nov 2018 01:30am EST 

Nov 20 (Reuters) - IPSEN SA ::IPSEN AND 3BP ANNOUNCE FIRST PATIENT DOSED IN PHASE I/II STUDY FOR FIRST-IN-CLASS RADIONUCLIDE (IPN01087).KEY OBJECTIVE OF PHASE I DOSE-ESCALATION TRIAL (EUDRACT NUMBER 2017-001263-20) IS TO EVALUATE SAFETY AND ACTIVITY.IPN01087 IS A COMPOUND THAT TARGETS CANCER CELLS IN PATIENTS WITH ADVANCED SOLID TUMORS WHICH EXPRESS NEUROTENSIN RECEPTOR SUBTYPE 1 (NTSR1).  Full Article

Ipsen Delivers Strong Sales Growth Of 20.2%1 For The Q3 2018 And Confirms Full Year Guidance
Thursday, 25 Oct 2018 01:00am EDT 

Oct 25 (Reuters) - Ipsen SA ::IPSEN DELIVERS STRONG SALES GROWTH OF 20.2%1 FOR THE THIRD QUARTER OF 2018 AND CONFIRMS FULL YEAR GUIDANCE.Q3 2018 GROUP SALES GROWTH OF 20.2%.FULL YEAR 2018 GUIDANCE CONFIRMED.FULL YEAR 2018 GUIDANCE CONFIRMED WITH GROUP SALES GROWTH OF GREATER THAN 19.0%1 AND CORE OPERATING MARGIN OF AROUND 29.0% OF SALES.Q3 GROUP SALES EUR 555.9 MILLION VERSUS EUR 470.1 MILLION YEAR AGO.  Full Article

Ipsen Receives Positive CHMP Opinion For Cabometyx
Friday, 21 Sep 2018 01:30am EDT 

Sept 21 (Reuters) - IPSEN SA ::IPSEN RECEIVES POSITIVE CHMP OPINION FOR CABOMETYX (CABOZANTINIB) FOR THE SECOND-LINE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC).CHMP POSITIVE OPINION WILL NOW BE REVIEWED BY EUROPEAN COMMISSION (EC).  Full Article

Ipsen Raises FY Guidance
Thursday, 26 Jul 2018 01:00am EDT 

July 26 (Reuters) - Ipsen SA ::H1 OPERATING INCOME EUR 269.7 MILLION VERSUS EUR 176.4 MILLION YEAR AGO.H1 CONSOLIDATED NET PROFIT EUR 197.3 MILLION VERSUS EUR 125.9 MILLION YEAR AGO.UPGRADED FULL YEAR 2018 GUIDANCE OF GROUP SALES GROWTH GREATER THAN 19.0%(1) (VERSUS PRIOR GUIDANCE GREATER THAN 16.0%) AND CORE OPERATING MARGIN OF AROUND 29.0% OF SALES (VERSUS PRIOR GUIDANCE GREATER THAN 28.0%).  Full Article

Ipsen’s Cabometyx receives approval from European Commission
Thursday, 17 May 2018 01:00am EDT 

May 17 (Reuters) - IPSEN SA ::EUROPEAN COMMISSION APPROVES IPSEN’S CABOMETYX® (CABOZANTINIB) FOR THE FIRST-LINE TREATMENT OF ADULTS WITH INTERMEDIATE- OR POOR-RISK ADVANCED RENAL CELL CARCINOMA.EC APPROVED CABOMETYX (CABOZANTINIB) 20, 40, 60 MG FOR FIRST-LINE TREATMENT OF ADULTS WITH INTERMEDIATE- OR POOR-RISK ARCC.THIS APPROVAL ALLOWS FOR MARKETING OF CABOMETYX (CABOZANTINIB) IN THIS INDICATION IN ALL 28 MEMBER STATES OF EUROPEAN UNION, NORWAY AND ICELAND.  Full Article

Photo

Trade tariff reprieve triggers relief in European shares

LONDON U.S. President Donald Trump's decision to delay an increase in tariffs on Chinese goods drove European shares to their highest since October with carmakers, most sensitive to the threat of a global trade war, leading the rally.